- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gastric Cancer | Clinical
Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors
November 10, 2021
The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.
Nivolumab/Ipilimumab Combo Misses Mark while Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer
September 19, 2021
Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.
Nivolumab/Ipilimumab Arm Misses Mark While Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer
September 19, 2021
The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.
Encouraging Activity Seen With Trastuzumab Deruxtecan in Western Patients With HER2+ Gastric/GEJ Cancer
September 17, 2021
In Western patients with HER2-positive gastric/gastroesophageal junction cancer Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate.
Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma Seen With Toripalimab/Chemo Combo
September 17, 2021
In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.
Limited Clinical Activity in Second-Line Gastric/GEJ Cancer Seen With Linagliptin/Atezolizumab Combo
September 16, 2021
Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab.
Gastric Cancer Therapy TST001 Receives FDA Orphan Drug Designation
July 30, 2021
The FDA has granted an orphan drug designation to TST001, an anti-Claudin18/2 monoclonal antibody, for the treatment of gastric cancer or gastroesophageal junction.
Pembrolizumab Withdrawn From US Market as Option For Third-Line Gastric or GEJ Adenocarcinoma
July 06, 2021
Pembrolizumab has been voluntarily withdrawn from the North American market as a treatment option for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Deep, Durable Responses Continue With Pembrolizumab and Trastuzumab in Gastric/GEJ Cancer
July 03, 2021
“We observed much more deeper responses and more meaningful responses [in the treatment arm] compared with the placebo arm, in which 15% of the population had deep responses of ≥ 80%."
Paclitaxel and GSK2636771 Combo Shows Benefit in Certain Patients with Gastric Cancer
July 02, 2021
The combination of paclitaxel and GSK2636771 showed encouraging antitumor activity and a manageable toxicity profile and in patients with PTEN-deficient advanced gastric cancer who progressed after first line chemotherapy.